Arcutis Biotherapeutics Inc (NASDAQ:ARQT) shares, rose in value on Thursday, March 27, with the stock price down by -2.31% to the previous day’s close as strong demand from buyers drove the stock to $16.09.
Actively observing the price movement in the last trading, the stock closed the session at $16.47, falling within a range of $15.96 and $16.5978. The value of beta (5-year monthly) was 1.488. Referring to stock’s 52-week performance, its high was $17.75, and the low was $6.99. On the whole, ARQT has fluctuated by 21.71% over the past month.
With the market capitalization of Arcutis Biotherapeutics Inc currently standing at about $1.91 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-24.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 301.79M, with a low estimate of 57.8M and a high estimate of 70M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 64.1M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ARQT’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of ARQT currently trading nearly 4.48% and 15.22% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 56.70, while the 7-day volatility ratio is showing 5.29% which for the 30-day chart, stands at 7.92%. Furthermore, Arcutis Biotherapeutics Inc (ARQT)’s beta value is 1.69, and its average true range (ATR) is 1.09.
A comparison of Arcutis Biotherapeutics Inc (ARQT) with its peers suggests the former has fared considerably weaker in the market. ARQT showed an intraday change of -2.31% in last session, and over the past year, it grew by 73.76%%.
Data on historical trading for Arcutis Biotherapeutics Inc (NASDAQ:ARQT) indicates that the trading volumes over the past 10 days have averaged 3.02 and over the past 3 months, they’ve averaged 2.32 million. According to company’s latest data on outstanding shares, there are 117.85 million shares outstanding.
Nearly 12.01% of Arcutis Biotherapeutics Inc’s shares belong to company insiders and institutional investors own 102.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.11 million shares as on 2025-03-14, resulting in a short ratio of 6.95. According to the data, the short interest in Arcutis Biotherapeutics Inc (ARQT) stood at 1570.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 17.64 million. The stock has risen by 15.51% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ARQT stock heading into the next quarter.
